Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Core Insights - Atossa Therapeutics presented a clinical trial update on (Z)-endoxifen, highlighting its potential to restore muscle performance and lower damage biomarkers in mdx5Cv dystrophic mice at the 2026 MDA Clinical & Scientific Conference [1] Group 1: Clinical Trial Findings - (Z)-endoxifen was well tolerated with no adverse findings observed during the study [1] - Key biochemical and histologic markers of muscle damage were reduced [1] - Favorable changes in body composition were noted, including increased lean mass and reduced fat mass [1] - The treatment enhanced resistance to contraction-induced muscle injury [1] - (Z)-endoxifen improved muscle strength and motor performance in both juvenile and adult dystrophic mice [1] Group 2: Clinical Significance - Duchenne Muscular Dystrophy (DMD) is a progressive and fatal neuromuscular disorder with significant unmet medical needs for additional therapies [1] - Preclinical findings suggest that (Z)-endoxifen may address multiple aspects of DMD pathology, including muscle weakness and functional decline [1] - The results support further clinical investigation of (Z)-endoxifen as a potential new therapeutic option for DMD patients [1] Group 3: About (Z)-Endoxifen - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with activity across multiple mechanisms [1] - The proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen [1] - Atossa's (Z)-endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents [1] Group 4: About Atossa Therapeutics - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies in oncology and other areas of significant unmet need [1] - The company's lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings [1] - Atossa emphasizes disciplined capital allocation to enable future regulatory submissions and potential commercialization [1]